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Many proteins in the eukaryotic cell are modified by O-linked 
N-acetylglucosamine (O-GlcNAc) on serines and threonines1. O-
GlcNAcylation has been shown to be important for regulation of
the cell cycle, DNA transcription and translation, insulin
sensitivity and protein degradation2,3. Misregulation of O-
GlcNAcylation is associated with diabetes and Alzheimer's
disease2,4,5. Two enzymes are involved in the dynamic cycling of
this posttranslational modification, the O-GlcNAc transferase
(OGT, classified as CAZY6 family GT41) and O-GlcNAcase
(OGA, GH84). PUGNAc (O-(2-acetamido-2-deoxy-D-
glucopyranosylidene)amino-N-phenylcarbamate), a nanomolar
inhibitor of OGA, has been extensively used to induce and study
the effects of raised O-GlcNAc levels in the cell7,8. However,
PUGNAc is also a potent inhibitor of the human lysosomal
hexosaminidases HexA and HexB, inactivation of which has been
associated with the Tay-Sachs and Sandhoff lysosomal storage
disorders. While more selective derivatives of PUGNAc and other
OGA inhibitors have recently been reported9,10,11, these are also
associated with weaker (micromolar) inhibition of OGA. Here we
report on a rationally designed glucoimidazole, GlcNAcstatin ((1),
Fig. 1), which inhibits a bacterial OGA (bOGA) with a Ki of 4.6
pM and 100000-fold selectivity over HexA/B, is active against
human OGA (hOGA) in human cell lines and is tethered in the
active site as revealed by X-ray crystallography.
Recent structural data of bOGA in complex with PUGNAc has 
shown that this compound mimics the sp2 configuration of the C1 
atom in the transition state and binds with the acetamido group in 
a deep pocket that is significantly smaller in HexA/HexB than in 
OGA12, providing an inroad to engineering selectivity. The 
PUGNAc phenylcarbamate moiety extends out of the active site 
towards a solvent exposed tryptophan. In an effort to increase 
affinity and selectivity in parallel, we decided to investigate the 
somewhat isosteric gluco-configured derivatives13 of the naturally 
occurring hexosaminidase inhibitor nagstatin14. In 1995 Tatsuta 
reported the total synthesis of this compound15 and a series of 
related glycoimidazole derivatives with variable configuration of 
the sugar ring, showing up to nanomolar inhibition against a panel 
of glycosidases16,17. Subsequent work by the Vasella group 
defined the structure-activity relationships of nagstatin analogues 
(tetrahydroimidazo[1,2-a]pyridines) as glycosidase inhibitors, 
making use of an original synthetic approach to the bicyclic core 
structure18, showing that the molecular architecture of these 
compounds in the ground state accurately mimics the assumed 
flattened half-chair/envelope conformation of the sugar ring in the 
transition state, while protonation of the imidazole ring effectively 
emulates the charge distribution in the oxocarbenium ion. 
Furthermore, critical evaluation of the nature of the C2 substituent 
showed that a glycon-mimicking group in this position results in 
stronger inhibition19,20. Combining the current body of knowledge 
on the glycoimidazoles together with the structural data of the 
bOGA-PUGNAc complex, we designed a series of GlcNAc 
configured nagstatin derivatives (GlcNAcstatins) that address 
specificity towards the OGA enzymes through elaborated N8 
(tetrahydroimidazopyridine numbering) acyl derivatives while 
providing a source of increased affinity through the incorporation 
of suitable C2 substituents. Here we report the synthesis of 
GlcNAcstatin (1, Fig. 1), a glucoimidazole with noticeable 
similarity to the molecular architecture of PUGNAc, but bearing a 
larger iso-butanamido group on N8 and a phenethyl group on C2.  
GlcNAcstatin was synthesized using a combination of the 
Tatsuta and Vasella approaches, as set out in the Supporting 
Information. Kinetic analysis using a previously published assay12 
(adapted for use with picomolar enzyme concentrations, see 
Supporting Information) shows that GlcNAcstatin is a very 
potent, competitive inhibitor of bOGA with a Ki of 4.6 ± 0.1 pM 
(Fig. 1). Direct measurement of a binding Kd either by isothermal 
titration calorimetry or intrinsic tryptophan fluorescence was not 
possible due to complete depletion of free inhibitor concentration 
in the picomolar range by even the lowest experimentally possible 
concentration of enzyme (data not shown).  
Figure 1. Structure of GlcNAcstatin and Lineweaver-Burk analysis of 
bOGA steady-state kinetics in the presence of inhibitor concentrations. 
Inhibition of HexA/B was also evaluated, giving a Ki of 0.52 
µM (see Supporting Information). Thus, GlcNAcstatin is 100000-
fold selective for the O-GlcNAcase active site compared to the 
structurally most closely related enzymes in the human cell. To 
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demonstrate the molecular basis of this selectivity, we 
characterized the binding mode of the inhibitor by determining the 
crystal structure of the bOGA-GlcNAcstatin complex to a 
resolution of 2.25 Å  (Fig. 2). Similar to the previously 
determined PUGNAc12 and thiazoline21 complexes, the sugar 
moiety of the inhibitor occupies a pocket in the enzyme and 
interacts with four conserved hydrogen bond donors/acceptors. 
The pyranose ring adopts a 4E conformation, similar to that 
observed in previously determined enzyme-glucoimidazole 
complexes22,23 and the PUGNAc complex12. Interaction with 
Asp297 and Asn396 forces the iso-butanamido group to adopt a 
conformation compatible with the proposed substrate-assisted 
catalysis mechanism9,12,21, with the carbonyl oxygen approaching 
the sp2 configured “anomeric” carbon to within 3.4 Å (Fig. 2). 
The terminal methyls of the iso-butanamido group penetrate a 
pocket formed by the conserved Tyr335 and Trp394 (Fig. 2). In 
HexA/B this pocket is significantly smaller, explaining why the 
larger acyl groups on the previously reported inhibitors9,10,11 
significantly increase the Ki against these enzymes. Asp298, the 
catalytic acid, is precisely positioned for the lateral protonation 
mechanism as proposed by Vasella18. The phenethyl group 
extends away from the active site, interacting with the solvent-
exposed Trp490.  
To evaluate the usefulness of GlcNAcstatin as a chemical tool 
to study the effects of inhibition of OGA in human cells, activity 
of the compound in human SH-SY5Y human neuroblastoma cell 
lysates and the HEK 293 cell line was evaluated qualitatively by 
Western blot analysis with an anti-O-GlcNAc antibody. Fig. 3A 
shows that GlcNAcstatin appears more active than PUGNAc in 
inhibiting bOGA from removing O-GlcNAc from proteins in SH-
SY5Y cell lysates. More importantly, when used to treat HEK 293 
cells, GlcNAcstatin qualitatively appears more efficient at raising 
O-GlcNAc levels than PUGNAc (Fig. 3B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Crystal structure of GlcNAcstatin (sticks with green carbon 
atoms) complexed to bOGA. Unbiased 2.25 Å |Fo|−|Fc|, φcalc (2.5σ) 
electron density for the inhibitor is shown in cyan. 
 
In conclusion, compound (1), GlcNAcstatin reported here 
represents a novel, potent and highly selective tool to study the 
role of the O-GlcNAc modification in the human cell. Several 
other inhibitors such as the thiazolines9 and PUGNAc 
derivatives10,11 carrying larger N2 acyl groups have very recently 
been reported. Whilst these compounds did improve the 
selectivity, showing weaker inhibition of HexA/B, they did so at 
the cost of also significantly reducing inhibition of OGA, with Kis 
increasing to the micromolar range. The work described here 
shows that it is possible to achieve both picomolar inhibition and 
exquisite selectivity with rationally designed glucoimidazoles. 
The structural data of the GlcNAcstatin complex will allow for 
further fine tuning of the inhibitory properties of GlcNAcstatin 
derivatives by elaboration of the N8 acyl group and the aromatic 
substituents off the imidazole ring. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Immunoblot detection of O-GlcNAc modifications on cellular 
proteins, compared to molecular weight standards in the far left lanes. A: 
bOGA (5 µM) activity on SH-SY5Y neuroblastoma cell lysates is 
inhibited by increasing amounts of PUGNAc/GlcNAcstatin, B: HEK293 
cells incubated for 12 h with increasing amounts of  inhibitors. 
Acknowledgement. We thank the ESRF for the time at ID14-
4. DvA is supported by a Wellcome Trust SRF and the Lister 
Prize, HCD by the College of Life Sciences Alumni Studentship. 
We thank Alan Fairlamb for fruitful discussions.   
 Supporting Information Available. Experimental details of 
synthesis of (1), enzyme inhibition and X-ray crystallography. 
References.  
(1) Torres, C. R.;  Hart, G. W. J.Biol.Chem. 1984, 259, 3308-3317.  
(2) Zachara, N. E.;  Hart, G. W. Biochim.Biophys.Acta 2004, 1673, 13-28.  
(3) Love, D. C.;  Hanover, J. A. Science STKE 2005, 312, 1-14.  
(4)Wells, L.;  Gao, Y.;  Mahoney, J. A.;  Vosseller, K.;  Chen, C.;  Rosen, A.;  
Hart, G. W. J.Biol.Chem. 2002, 277, 1755-1761.  
(5)Lehman, D. M et al. Diabetes 2005, 54, 1214-1221.  
(6) http://afmb.cnrs-mrs.fr/CAZY 
(7) Horsch, M.;  Hoesch, L.;  Vasella, A.;  Rast, D. M. Eur.J.Biochem. 1991, 
197, 815-818.  
(8) Haltiwanger, R. S.;  Grove, K.;  Philipsberg, G. A. J.Biol.Chem. 1998, 273, 
3611-3617.  
(9)Macauley, M. S.;  Whitworth, G. E.;  Debowski, A. W.;  Chin, D.;   
Vocadlo, D. J. J.Biol.Chem. 2005, 280, 25313-25322.  
(10) Stubbs, K. A.;  Zhang, N.;  Vocadlo, D. J. Org.Biomol.Chem. 2006, 4, 
839-845.  
(11) Kim, E. J.;  Perreira, M.;  Thomas, C. J.;  Hanover, J. A. J.Am.Chem.Soc. 
2006, 128, 4234-4235.  
(12)Rao, F. V.;  Dorfmueller, H. C.;  Villa, F.;  Allwood, M.;   
Eggleston, I. M.;  van Aalten, D. M. F. EMBO J. 2006, 25, 1569-1578.  
(13) Terinek, M.;  Vasella, A. Helv.Chim. Acta 2005, 88, 10-22.  
(14)Aoyagi, T.;  Suda, H.;  Uotani, K.;  Kojima, F.;  Aoyama, T.;  Horiguchi, K
.;  Hamada, M.;  Takeuchi, T. J.Antibiot. 1992, 45, 1404-1408.  
(15) Tatsuta, K.;  Miura, S. Tetrahedron Lett. 1995, 36, 6721-6724.  
(16) Tatsuta, K.;  Miura, S.;  Ohta, S.;  Gunji, H. J.Antibiot. 1995, 48, 286-288.  
(17) Tatsuta, K.;  Miura, S.;  Ohta, S.;  Gunji, H. Tetrahedron Lett. 1995, 36, 
1085-1088.  
(18) Heightman, T. D.;  Vasella, A. T. Angew.Chem.-Int.Edit. 1999, 38, 750-
770.  
(19) Panday, N.;  Canac, Y.;  Vasella, A. Helv.Chim.Acta 2000, 83, 58-79.  
(20) Shanmugasundaram, B.;  Vasella, A. Helv.Chim.Acta 2005, 88, 2593-
2602.  
(21)Dennis, R. J.;  Taylor, E. J.;  Macauley, M. S.;  Stubbs, K. A.;   
Turkenburg, J. P.;  Hart, S. J.;  Black, G. N.;  Vocadlo, D. J.;   
Davies, G. J. Nat.Struct.Mol.Biol. 2006, 13, 365-371.  
(22)Hrmova, M.;  Streltsov, V. A.;  Smith, B. J.;  Vasella, A.;   
Varghese, J. N.;  Fincher, G. B. Biochemistry 2005, 44, 16529-16539.  
(23)Gloster, T. M.;  Roberts, S.;  Perugino, G.;  Rossi, M.;  Moracci, M.;  
 Panday, N.;  Terinek, M.;  Vasella, A.;  Davies, G. J. Biochemistry 2006, 
45, 11879-11884. 
 
 
ABSTRACT FOR WEB PUBLICATION  
Many phosphorylation signal transduction pathways in the eukaryotic cell are modulated by posttranslational modification of 
specific serines/threonines with N-acetylglucosamine (O-GlcNAc). Levels of O-GlcNAc on key proteins regulate biological 
processes as diverse as the cell cycle, insulin signalling and protein degradation. The two enzymes involved in this dynamic 
and abundant modification are the O-GlcNAc transferase and O-GlcNAcase. Structural data has recently revealed that the O-
GlcNAcase possesses an active site with significant structural similarity to the human lysosomal hexosaminidases 
HexA/HexB. PUGNAc, an O-GlcNAcase inhibitor widely used to raise levels of O-GlcNAc in human cell lines, also inhibits 
these hexosaminidases. Here, we have exploited recent structural information of an O-GlcNAcase-PUGNAc complex to 
design and synthesize a glucoimidazole-based inhibitor, GlcNAcstatin, which is a 5 picomolar competitive inhibitor of enzymes 
of the O-GlcNAcase family, shows 100000-fold selectivity over HexA/B and binds to the O-GlcNAcase active site by mimicking 
the transition state as revealed by X-ray crystallography. This compound is able to raise O-GlcNAc levels in human HEK 293 
and SH-SY5Y neuroblastoma cell lines, and thus provides a novel, potent tool for the study of the role of O-GlcNAc in 
intracellular signal transduction pathways. 
